Ayala-led Health Firm Inks Partnership with Fibronostics

In a bid to further expand its digital portfolio, Ayala Healthcare Holding, Inc. (AC Health), through its technology arm, Vigos, has embarked on a partnership with US-based healthcare technology company Fibronostics.

Ayala-led Health Firm Inks Partnership with Fibronostics

Through the agreement, which was signed by AC Health President and CEO Paolo Borromeo, AC Health Chief Digital Officer, Christian Besler, and SPRIM Ventures Managing Partner, Dr. Michael Shleifer last May 31, 2019, AC Health will launch two Fibronostics products -- LiverFAST and HealthFACTOR in its FamilyDOC clinics.

LiverFAST is a proprietary algorithm that analyzes 10 biomarkers from a blood sample to help screen and monitor common liver diseases. The test is intended to be a simple and less expensive option for other diagnostics, such as liver biopsy or liver imaging. HealthFACTR, on the other hand, is as a 10-minute metabolic health check-up solution that provides immediate risk assessment and personalized recommendations, based on the latest medical guidelines.

Taking pride in Vigos as the first digital health portfolio in the Philippines, Borromeo shared that the partnership attests to AC Health’s commitment to providing quality care for their patients.

“This investment fits well into our Vigos health technology portfolio, which we are proud to say is the first digital health portfolio in the Philippines. We are always on the lookout for technology solutions that empower our doctors and improve quality for our patients,” said Borromeo.

Meanwhile, Dr. Shleifer believes that the partnership would encourage more patients to appreciate the value of screening and preventive health.

“We are very excited to collaborate with AC Health. Through their network of FamilyDOC clinics, we hope to reach many more patients in the Philippines, where the burden of chronic diseases has been growing. Ultimately, our goal is to screen patients early so that they can work in partnership with their doctors to maintain good health and prevent complications,” shared Dr. Shleifer.

Since its establishment in 2015, Fibronostics has been providing non-invasive products that are made to improve medical screening, follow-up, and diagnosis, focusing on common chronic conditions like liver disease, coronary heart disease, stroke, diabetes, and obstructive sleep apnea.